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Bleomycin has a chemical toxicity capable of inducing the hydroxyproline content in the skin was significantly
reduced, as compared with mice treated with bleomy-superoxide radicals, which are suggested to play an
cin only or bleomycin and 5% mannitol. In a separateimportant part in bleomycin-induced pulmonary fib-
experiment, after the development of dermal sclerosisrosis. We have recently established a mouse model for
following treatment with bleomycin for 3 wk, PC-scleroderma induced by repeated local injections of
superoxide dismutase was administered for 2 wk.bleomycin. In this study, we examined the inhibitory
Histologic examination again revealed a reduction ofeffect of superoxide dismutase on the development of
dermal sclerosis, followed by a significant associate indermal sclerosis induced by bleomycin using this
the number of both mast cells and eosinophils. Themouse model. PC-superoxide dismutase, which is a hydroxyproline content in the skin was not significantlylecithinized superoxide dismutase with high tissue decreased, however, even after injections of high
accumulation and long half-life in blood, was adminis- amounts of PC-superoxide dismutase (30,000 U per
tered (3000 U per kg; dissolved in 5% mannitol) 3 h kg). These results support the involvement of oxygen
before the injection of bleomycin in C3H mice for free radicals in bleomycin-induced dermal sclerosis,
3 wk. Systemic PC-superoxide dismutase markedly and also indicate that administration of superoxide
inhibited the development of dermal sclerosis, which dismutase may be effective in the therapeutic approach
was also accompanied by a decrease in the number of in systemic sclerosis. Key words: animal model/bleomycin/
scleroderma/superoxide. J Invest Dermatol 113:843–847, 1999infiltrating mast cells and eosinophils. Furthermore,
S in the immune system, including T cells, macrophages, and mastcells, may contributed to extracellular matrix deposition and vasculardamage in SSc.Peripheral neutrophils produce high levels of reactive oxygenspecies (ROS) in association with the severity and extent of skinystemic superoxide (SSc) is a connective tissue diseasewhich involves not only the skin but also various internalorgans leading to fibrosis with excessive collagen depos-ition. Although the pathogenesis of SSc is still unknown,the primary event is supposed to be an injury to endothel-
ial cells (LeRoy et al, 1989), and it is well known that inflammatory involvement in patients with SSc (Maslen et al, 1987; Law et al,
1992). Recent studies have focused on the interaction of circulatingcells infiltrate in the dermis during the early phase of SSc (Fleisch-
phagocytes, mainly (PMN), with endothelial cells and the potentiallymajer et al, 1977). These inflammatory cells are seen in association
cytotoxic effects of phagocyte products, including ROS (Harlan,with signs of endothelial injury with enhanced expression of
1987). Increased free radical production is supposed to be involvedadhesion molecules. The most likely explanation for the prolifera-
in the pathogenesis of SSc as an important initiator of tissue damage.tion of the intimal vascular wall is a sequence of events that follows
Bleomycin-induced lung injury is a well-known mouse modelendothelial injury, platelet adhesion as well as aggregation, and
which resembles human pulmonary fibrosis histologically andrelease of platelet-derived growth factor (PDGF) and transforming
biochemically (Aso et al, 1976; Adamson, 1984; Chandler, 1990).growth factor-β (TGF-β) (Gibbons and Dzau, 1994). TGF-β,
It is widely accepted that pulmonary fibrosis is in part due to anPDGF, tumor necrosis factor-α (TNF-α), or several interleukins
imbalance of oxidants and antioxidants (Strausz et al, 1990; Wallaert(IL-1, IL-2, IL-4, IL-6) are suggested to play a part in the
et al, 1990). Oxygen free radicals are important initiators of tissuepathogenesis of SSc. These cytokines produced by activated cells
damage (McCord, 1985), and there is also evidence that oxygen
radicals are involved in bleomycin-induced lung injury (Hakkinen,
1982; Frank, 1983). Bleomycin is known to generate ROS, such
Manuscript received June 17, 1999; revised July 30, 1999; accepted for as superoxide and hydroxyl radicals (Oberley and Buettner, 1979;publication August 5, 1999. Ekimoto et al, 1980; Guttering and Xiai-Chang, 1981). TheReprint requests to: Dr Toshiyuki Yamamoto, Department of
hypothesis that bleomycin leads to the generation of oxygenDermatololgy, Tokyo Medical and Dental University, School of Medicine,
metabolites is supported by the fact that hypoxia protects against1–5-45 Yushima, Bunkyo-ku, Tokyo 113, Japan.
the effects of intratracheal bleomycin and that hyperoxia vice versaAbbreviations: ROS, reactive oxygen species, SOD, superoxide
dismutase; SSc, systemic sclerosis augments bleomycin-induced injury (Tryka et al, 1982; Berend,
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1984). The exact mechanism of bleomycin-induced lung damage
is not completely understood; however, it is believed that the initial
injury caused by this agent involves binding to DNA and Fe21,
and this complex is thought to generate ROS under aerobic
conditions (Giri and Wang, 1989).
Superoxide dismutase (SOD) is a family of enzymes that catalyze
the dismutation of O2
– to H2O2 and O2. Several different SOD
have evolved to inactivate both intracellular and extracellular
superoxide (Fridovich, 1995; Tsan, 1997). Human CuZn–SOD
has been shown to be effective in a variety of animal models. We
have recently established a mouse model for scleroderma induced
by bleomycin (Yamamoto et al, 1999). In this model, dermal sclerosis
mimicking human SSc both histologically and biochemically was
induced by repeated local injections of bleomycin for 4 wk in
BALB/c mice and for 3 wk in C3H mice. In this study, we have
examined the therapeutic effect of PC-SOD, which has been
modified in order to have a higher accumulation in the tissue and
a longer half-life in peripheral blood (Igarashi et al, 1992, 1994),
in the formation of bleomycin-induced dermal sclerosis in mice.
Figure 1. Representative photomicrographs of hematoxylin and
eosin (H&E) staining showing effects of SOD on bleomycin-MATERIALS AND METHODS
induced dermal sclerosis. Simultaneous treatment of bleomycin and
Mice Specific pathogen-free female, 6 wk old C3H mice (purchased intravenous administration of PC-SOD (3000 U per kg) for 2 wk
from Sankyo Co., Tokyo, Japan), weighing 20–25 g, were used. Mice demonstrated a significant decrease of sclerotic lesions, with slight fibrosis
were kept in separate clean rooms ad libitum. and mild cellular infiltration of mononuclear cells (A). In contrast, mice
treated with bleomycin and intravenous administration of 5% mannitol
Induction of dermal sclerosis by bleomycin and administration of showed a definite sclerotic skin with thickened collagen bundles and
PC-SOD As previously described (Yamamoto et al, 1999), mice were homogeneous deposition (B). (Original magnification, 3170.)
treated by local bleomycin injections on the back. C3H mice had been
demonstrated to develop dermal sclerosis by subcutaneous daily bleomycin
injections for 3 wk. First, mice were randomly classified into three groups RESULTS
(n58 in each group) for the bleomycin treatment. One group received
Administration of PC-SOD exhibits inhibitory effects ononly bleomycin (100 µg per ml; diluted in phosphate-buffered saline)
treatment; one group received intravenous injections of 100 µl of PC- the development of dermal sclerosis induced by
SOD (generous gift from Seikagaku Kogyo Co. Ltd, Tokyo, Japan) (3000 U bleomycin At first, we examined the inhibitory effect of PC-
per kg; diluted in 5% mannitol and filtrated by 0.2 µm filter) (decided in SOD administered together with bleomycin on the induction of
a preliminary experiment) 3 h before treatment with bleomycin. The third dermal sclerosis. In preliminary experiments, it was demonstrated
group received injections with bleomycin and 5% mannitol in the same that administration of bleomycin for 3 wk induced dermal sclerosisamounts as the second group. In a separate experiment, PC-SOD was
in C3H mice. Therefore, PC-SOD was also applied for 3 wk.intravenously administered after the onset of dermal sclerosis induced by
Daily administration of intravenous injections of PC-SOD (3000 Urepeated injections of bleomycin for 3 wk in C3H mice. Mice were killed
per kg) with subcutaneous injections of bleomycin (100 µg perby cervical dislocation the next day after the final treatment, and the back
ml) for 3 wk attenuated the dermal sclerosis in C3H mice (Figskin was harvested for further examination.
1A). A mild inflammatory infiltrate of mononuclear cells was
detected in the lower dermis. In contrast, control mice treatedHistopathologic analysis Tissue specimens were fixed in 10% formalin
solution and embedded in paraffin. The general histologic appearance of with bleomycin alone, and bleomycin together with mannitol,
the tissue was examined by routine hematoxylin and eosin staining. both showed a marked dermal sclerosis (Fig 1B). Analysis of
Skin specimens were assessed and scored to provide a semiquantitative the histologic results showed that administration of PC-SOD
measurement of dermal inflammation (0, none; 1, little; 2, mild; 3, significantly reduced the degree of dermal thickness and thickened
moderate; 4, severe), thickened collagen bundles (0, normal; 1, little; 2, collagen bundles, whereas the degree of cellular infiltrates in themild; 3, moderate; 4, severe), and dermal thickness compared with normal
dermis was not significantly decreased (Fig 2). Hyalinization andskin (0, ,125%; 1, 125–150%; 2, 150–175%; 3, 175–200%; 4, .200%).
sclerosis of the vascular wall was also diminished. Mast cells areDermal thickness was measured after taking photographs.
suggested to play an important part in SSc, because the number of
mast cells is increased in early scleroderma (Nishioka et al, 1987).Morphometric analysis Mast cells containing metachromatic granules
Eosinophils are also occasionally seen in scleroderma skin, andwere identified by Toluidine Blue staining at a pH of 2.5, 4.1, and 7.0.
suggested to be one of the responsible cells for TGF-β (Zang et al,Eosinophils were identified by their polymorphonuclear morphology and
characteristic staining by Giemsa or 1% Congo Red. The numbers of mast 1995). Based on these findings, we examined the numbers of these
cells and eosinophils were quantified by counting 10 randomly chosen cells after SOD treatment. Mast cells were significantly decreased
high power fields (HPF; 3400) using an ocular grid of a light microscope, (17.261.6/HPF in mannitol treatment vs. 8.062.2/HPF in PC-
and the mean number of cells was calculated. SOD treatment, p,0.05), and eosinophils were also significantly
reduced (7.061.1/HPF in mannitol treatment vs. 2.360.9/HPF
Hydroxyproline assay Six millimeter punch biopsy specimens were in PC-SOD treatment, p,0.05) after treatment with SOD for 3 wk.
excised from the shaved back skin of each mouse, and stored at –80°C.
Collagen deposition was estimated by determining the total hydroxyproline Hydroxyproline content is increased in the skin after bleomy-
content of the skin. The biopsies were hydrolyzed with 6 M hydrochloric cin treatment, which is abrogated after administration of
acid under 110°C for 18 h as previously described (Woessener, 1961). PC-SOD and bleomycin As we have previously observed
After neutralization with sodium hydroxide, the hydrolysates were diluted (Yamamoto et al, 1999), hydroxyproline contents in the skinwith distilled water. The amount of hydroxyproline in the hydrolysates
are increased in bleomycin-induced scleroderma skin. Next, wewas assessed colorimetrically at 560 nm with p-dimethylaminobenzaldehyde.
examined whether the amount of hydroxyproline is decreased afterResults were expressed as micrograms hydroxyproline per skin.
administration of PC-SOD, in parallel with histologic improvement.
Treatment with injections of bleomycin and mannitol for 3 wkStatistical analysis Results were expressed as mean6SD. Significance
induced an increase of the hydroxyproline content in the skin fortesting was analyzed using Mann–Whitney U-test. A p,0.05 was considered
to be significant. up to 177615% as compared with normal skin, whereas bleomycin
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Figure 2. Summary of the effects of SOD on cutaneous
histopathology. Shown are the mean6SD of the scores determined as
described in Materials and methods. *Groups that were significantly different
(p,0.05) from the control mice treated with bleomycin only for each
histopathologic parameter.
Figure 4. Effects of administration of SOD after onset of dermal
sclerosis on the cutaneous histopathology. Intravenous administra-
tion of PC-SOD (3000 U per kg) for 2 wk reduced the dermal sclerosis
(A), compared with intravenous mannitol treatment (B). (Original magni-
fication, 3170.)
Figure 3. Effects of SOD on bleomycin-induced dermal sclerosis.
Cutaneous sclerosis was assessed by measurement of skin hydroxyproline
content after 3 wk of treatment. Bleomycin-induced cutaneous sclerosis
was significantly inhibited by treatment with simultaneous administration
of intravenous PC-SOD for 3 wk, compared with that in mice treated
with intravenous mannitol (*p,0.05).
treatment together with PC-SOD showed an increase of only
130611%. This difference reached a statistical significance (p,0.05)
(Fig 3).
Intravenous injections of PC-SOD after onset of bleomycin-
induced scleroderma does not improve sclerosis The post-
onset situation is a much more stringent test of the ability of PC-
SOD to inhibit scleroderma, as dermal thickness with thickened
collagen bundles, collagen deposition, and cellular infiltrates are
already going on when the treatment is started. Furthermore, post-
onset effects more closely reflect a clinical situation where symptoms
are already apparent. To test the effects of PC-SOD on existing
Figure 5. Effects of post-onset treatment with SOD on cutaneousdermal sclerosis, we first treated C3H mice with bleomycin (100 µg
histopathology. Shown are the mean6SD of the assessment values forper ml) for 3 wk. Then, after the development of dermal sclerosis, the indicated parameters. *Groups that were significantly different (p,0.05)
PC-SOD was given intravenously at a dose of 3000 and 30,000 U from the control mice treated with bleomycin only for each
per kg daily for 2 wk. Histologic evaluation revealed a reduction histopathologic parameter.
of dermal sclerosis (Fig 4A,B). Analysis of the histologic changes
indicates that the group receiving PC-SOD showed significantly DISCUSSIONlower collagen thickness and dermal thickness in the post-onset
administration of PC-SOD experiment (Fig 5). A decrease of In this study, we demonstrated a therapeutic effect of PC-SOD on
bleomycin-induced dermal sclerosis in an experimental mousehyalinization and sclerosis of the vascular wall was found as well.
Hydroxyproline content in the skin was slightly decreased model. Intravenous administration of SOD inhibited sclerosis not
only when given simultaneously with bleomycin injection but alsobut this decrease failed to show a significant difference after
administration of PC-SOD 3000 or 30,000 U per kg (Fig 6). when given after the development of bleomycin-induced sclerosis,
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indicates that monocytes contribute to the increased production of
superoxide anion in patients with SSc (Sambo et al, 1999). ROS
can cause several abnormalities such as endothelial cell damage or
enhanced platelet activation, leading to an upregulation of the
expression of adhesion molecules or the secretion of inflammatory
or fibrogenic cytokines including PDGF and TGF-β. In this study,
the application of SOD together with bleomycin from the initial
stage resulted in a significant reduction of dermal sclerosis, in
contrast to post-onset administration of SOD after the induction
of sclerosis by bleomycin. Therefore, we hypothesized that if
bleomycin-related oxidative stress triggers sclerosis, then perhaps
SOD protects from initiation. Our results in fact suggest that it is
important to administer SOD before the development of sclerosis,
and post-onset administration is insufficient to prevent the pro-
gression.
Superoxide radicals produced as by-products of metabolic oxida-
tion can cause extensive cellular injury, and the elimination ofFigure 6. Effects of post-onset administration of SOD on skin
excess superoxide may be important for the control of oxygenhydroxyproline content. Intravenous administration of PC-SOD showed
radical related diseases. Because of the likely important role fora mild reduction of hydroxyproline content; however, the difference did
reactive oxidants in causing injury to cellular constituents, anti-not reach any significance even when the dose of PC-SOD was increased
oxidant therapy has been used in animal models of lung injury.for up to 30,000 U per kg.
Several studies have shown modulation of bleomycin-induced
pulmonary fibrosis with anti-oxidant therapies such as Mn–SOD,
taurine, niacin, N-acetylcysteine, and amifostine (Parizada et al,which was also histologically apparent with reduced thickened
collagen bundles. This effect lasted at least 4 wk after the final 1991; Shahzeidi et al, 1991; Wang et al, 1991; Nici et al, 1998).
SOD has evolved to inactivate both intracellular and extracellulartreatments (data not shown). Cellular infiltrates of the sclerotic skin
were rather mild both before and after the administration of superoxide (Fridovich, 1995; Tsan, 1997). CuZu–SOD and Mn–
SOD are normally present in cells in sufficient amounts to scavengeSOD, although variations were found between individual mice.
Administration of PC-SOD after the development of dermal intracellular O2
–. Although extracellular SOD has been reported
to protect the extracellular space and endothelial cell surface, thesclerosis could not significantly reduce skin hydroxyproline content,
even when the dose was increased up to 30,000 U per kg. activity of extracellular SOD is low (Marklund, 1984; Karlsson and
Marklund, 1989), which suggests that exogenous SOD may be ofHydroxyproline is a major constituent of collagen. Dermal sclerosis
was histologically reduced, but still retained, by post-onset adminis- clinical value by scavenging excess O2
– at the cell membrane. PC-
SOD has been shown to have a high affinity to the cell membrane,tration of PC-SOD. This may explain the discrepancy between
histologic and biochemical evaluation, and the results indicate that a high cellular uptake for both endothelial cells and neutrophils,
and delayed plasma disappearance compared with unmodified SOD,early administration is important to obtain sufficient effects. In
contrast, local injections of PC-SOD did not show any effects (data and the pharmacologic activities are over 200 times more than
those of unmodified SOD (Igarashi et al, 1992, 1994). The SODnot shown).
Using bleomycin, a number of studies have been performed to concentrations are assessed by enzyme-linked immunosorbent assay
in the 6 mm punch-biopsied skins, which were all below thegenerate models of pulmonary fibrosis in animals. Bleomycin
upregulates the synthesis of type I collagen in lung and dermal detectable limits through the course of the experiments. One
explanation is due to the small size of the samples, because dermalfibroblasts (Kaelin et al, 1983). Other data, however, showed that
bleomycin in culture with lung slices significantly reduces the sclerosis is induced limited to the injected sites.
A recent report has demonstrated that several autoantigensuptake of labeled proline into lung tissue, and inhibits hydroxylation
of proline into collagen, suggesting that the bleomycin-induced targeted by scleroderma autoantibodies are fragmented in the
presence of ROS and specific metals such as iron or copperincrease in collagen synthesis in vivo is not directly mediated (Phan
et al, 1991). In addition, bleomycin stimulates endothelial cells to (Casciola-Rosen et al, 1997). They therefore suggest that the
metabolism of the metals is important for the formation of freesynthesize TGF-β at the protein and messenger levels, as well as
to upregulate collagen synthesis in fibroblasts (Phan et al, 1991). radical damage and abnormal accumulation of cellular metal might
be of critical pathogenic importance in scleroderma. These findingsBleomycin is known to generate ROS, such as superoxide and
hydroxyl radicals. Several studies have shown the mechanism by support the notion that scleroderma is also characterized by isch-
emia–reperfusion injury; overproduction of ROS is commonlywhich oxygen radicals are formed, suggesting a participation of the
Fenton reaction in which the iron acts as a redox agent (Chandler found in scleroderma patients with active disease, and that sclerod-
erma is occasionally associated with a variety of environmentalet al, 1985, 1988a,b). Bleomycin complexes with free iron intracellu-
larly and, when bound to DNA, targets Fenton-driven OH toxins, such as silica or organic solvents. In conclusion, our results
suggest that ROS is involved in the formation of bleomycin-formation to the DNA. Iron has been shown to be a critical
cofactor for the activity of prolyl hydroxylase, which is a key induced dermal sclerosis in this mouse model, and the cellular
infiltrate observed in this model probably plays a crucial part in theenzyme in collagen synthesis, and the involvement of free radical
was shown during the formation of hydroxylated proline by prolyl development of the skin lesions. Our data also suggest the possibility
of a therapeutic role for SOD in scleroderma.hydroxylase (Bhatnagar and Liu, 1972). Therefore, a reduction of
free radical formation may contribute to the decrease of collagen
content by inhibition of proline hydroxylation. Increased free
radical production is supposed to be involved in the pathogenesis
This work was supported in part by a grant of the Scleroderma Research of theof SSc as an important initiator of tissue damage (Murrel, 1993;
Japanese Ministry of Health and Welfare.Herrick et al, 1994; Stein et al, 1996; Sambo et al, 1999). The exact
species produced, the mechanisms and sites of production, and the
consequences of these ROS, however, are still unknown. Peripheral
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